StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 6, 2026, 06:13 AM

Geron Q2 RYTELO Revenue $57.5M; Reiterates 2026 Guidance

AI Summary

Geron Corporation reported its second quarter 2026 financial results, with RYTELO net product revenue reaching $57.5 million, an 11% increase from the previous quarter. The company reiterated its full-year 2026 RYTELO net product revenue guidance of $220 million to $240 million and total operating expenses guidance of $230 million to $240 million. Geron ended the quarter with $327 million in cash and marketable securities, which is expected to fund operations for the foreseeable future. The company also highlighted a 5% growth in RYTELO demand and an 8% increase in ordering accounts during the quarter, alongside the appointment of a new Chief Business Officer.

Key Highlights

  • Reported RYTELO net product revenue of $57.5 million in Q2 2026, an 11% increase from Q1 2026.
  • Reiterated 2026 RYTELO net product revenue guidance of $220 million to $240 million.
  • Reiterated 2026 total operating expenses guidance of $230 million to $240 million.
  • Ended Q2 2026 with $327 million in cash, cash equivalents, restricted cash, and marketable securities.
  • Net loss for Q2 2026 was $16.7 million, or $0.02 per share, compared to $16.4 million in Q2 2025.
  • RYTELO demand grew by 5% in Q2 2026 compared to Q1 2026.
  • Increased RYTELO ordering accounts by approximately 8% to 1,575 in Q2 2026.
  • Appointed Chinmaya Rath as Chief Business Officer.